Neuropsychiatric manifestations in pediatric systemic lupus erythematosus: a 20-year study

Abstract

The objective of this study was to investigate the manifestations, treatment and outcome of neuropsychiatric (NP) involvement in pediatric systemic lupus erythematosus (SLE) patients. The charts of 185 pediatric patients with SLE diagnosed between 1985 and 2005 in a tertiary referral hospital were retrospectively reviewed. NPSLE were defined using the American College of Rheumatology NPSLE case definitions. NPSLE developed in 34.6% (64/185) of the patients. The mean onset age was 15.2 years. Fourteen patients (21.9%) had NP manifestations on initial diagnosis of SLE. The median duration from the onset of SLE to NP manifestation was 11 months. The most frequent NP manifestations were seizure disorder (84.4%), ischemic stroke (28.1%) and psychosis (21.9%). However, the prevalence of manifestations of NPSLE might be underestimated by the retrospective design of our study. Higher mean C3/C4 levels, less percentage of anti-dsDNA antibodies elevation and higher percentage of elevated anticardiolipin antibodies were observed in NPSLE events than in non-NPSLE events (P 0.05). The mortality rate of NPSLE patients decreased from 52.2% in 1985–1994 cohort to 27.8% in 1995–2005 cohort. In the past 10 years, the leading cause of death in NPSLE patients was NPSLE itself. NPSLE is common in pediatric SLE patients. It has diverse manifestations and a high mortality.

Keywords

systemic lupus erythematosus (SLE)neuropsychiatric manifestations

Get full access to this article

View all access options for this article.

References

The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes . Arthritis Rheum 1999; 42: 599–608 (review).

Parikh S , Swaiman KF , Kim Y . Neurologic characteristics of childhood lupus erythematosus . Pediatr Neurol 1995; 13: 198–201 .

Yancey CL , Doughty RA , Athreya BH . Central nervous system involvement in childhood systemic lupus erythematosus . Arthritis Rheum 1981; 24: 1389–1395 .

Quintero-Del-Rio AI , Miller V . Neurologic symptoms in childrem with systemic lupus erythematosus . J Child Neurol 2000; 12: 803–807 .

Olfat MO , Al-Mayouf SM , Muzaffer MA . Pattern of neuropsychiatric manifestations and outcome in juvenile systemic lupus erythematosus . Clin Rheumatol 2004; 23: 395–399 .

Sibbitt WL Jr , Brandt JR , Johnson CR et al. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus . J Rheumatol 2002; 29: 1536–1542 .

Eber T , Chapman J , Shoenfeld Y . Anti-ribosomal P-protein and its role in psychiatric manifestations of systemic lupus erythematosus: myth or reality? Lupus 2005; 14: 571–575 .

Isshi K , Hirohata S . Differential roles of the anti-ribosomal P antibody and antineuronal antibody in the pathogenesis of central nervous system involvement in systemic lupus erythematosus . Arthritis Rheum 1998; 41: 1819–1827 .

Sanna G , Bertolaccini ML , Cuadrado MJ et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies . J Rheumatol 2003; 30: 985–992 .

10.

Baca V , Lavalle C , Garcia R et al. Favorable response to intravenous methylprednisolone and cyclophosphamide in children with severe neuropsychiatric lupus . J Rheumatol 1999; 26: 432–439 .

11.

Mok CC , Lau CS , Wong RW . Neuropsychiatric manifestations and their clinical associations in southern Chinese patients with systemic lupus erythematosus . J Rheumatol 2001; 28: 766–771 .

12.

Al-Mayouf SM , Bahabri S . Spinal cord involvement in pediatric systemic lupus erythematosus: case report and literature review . Clin Exp Rheumatol 1999; 17: 505–508 (review).

13.

Vyas S , Hidalgo G , Baqi N , Von Gizyki H , Singh A . Outcome in African-American children of neuropsychiatric lupus and lupus nephritis . Pediatr Nephrol 2002; 17: 45–49 .

14.

Hochberg MC . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1997; 40: 1725–1726 .

15.

Shimojima Y , Matsuda M , Gono T , Ishii W , Ikeda SI . Relationship between clinical factors and neuropsychiatric manifestations in systemic lupus erythematosus . Clin Rheumatol 2005; 24: 469–475 .

16.

Winfield JB , Brunner CM , Koffler D . Serologic studies in patients with systemic lupus erythematosus and central nervous system dysfunction . Arthritis Rheum 1978; 21: 289–294 .

17.

Campos LM , Kiss MH , D’Amico EA , Silva CA . Antiphospholipid antibodies and antiphospholipid syndrome in 57 children and adolescents with systemic lupus erythematosus . Lupus 2003; 12: 820–826 .

18.

Szer IS , Miller JH , Rawlings D , Shaham B , Bernstein B . Cerebral perfusion abnormalities in children with central nervous system manifestations of lupus detected by single photon emission computed tomography . J Rheumatol 1993; 20: 2143–2148 .

19.

Reiff A , Miller J , Shaham B , Bernstein B , Szer IS . Childhood central nervous system lupus; longitudinal assessment using single photon emission computed tomography . J Rheumatol 1997; 24: 2461–2465 .

20.

Russo R , Gilday D , Laxer RM , Eddy A , Silverman ED . Single photon emission computed tomography scanning in childhood systemic lupus erythematosus . J Rheumatol 1998; 25: 576–582 .

21.

Milstone AM , Meyers K , Elia J . Treatment of acute neuropsychiatric lupus with intravenous immunoglobulin (IVIG): a case report and review of the literature . Clin Rheumatol 2005; 24: 394–397 .

22.

Neuwelt CM , Lacks S , Kaye BR , Ellman JB , Borenstein DG . Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus . Am J Med 1995; 98: 32–41 .

23.

Takada K , Illei GG , Boumpas DT . Cyclophosphamide for the treatment of systemic lupus erythematosus . Lupus 2001; 10: 154–161 .

24.

Trevisani VF , Castro AA , Neves Neto JF , Atallah AN . Cyclophosphamide versus methylprednisolone for the treatment of neuropsychiatric involvement in systemic lupus erythematosus . Cochrane Database Syst Rev 2000; 3: CD00 22-65 .

25.

Sanna G , Bertolaccini ML , Mathieu A . Central nervous system lupus: a clinical approach to therapy . Lupus 2003; 12: 935–942 .

26.

Bodani M , Kopelman MD . A psychiatric perspective on the therapy of psychosis in systemic lupus erythematosus . Lupus 2003; 12: 947–949 .

27.

McCune WJ , Golbus J , Zeldes W , Bohlke P , Dunne R , Fox DA . Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus . N Engl J Med 1988; 318: 1423–1431 .

28.

Neuwelt CM. The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus . Ther Apher Dial 2003; 7: 173–182 .

29.

Valesini G , Priori R , Francia A et al. Central nervous system involvement in systemic lupus erythematosus: a new therapeutic approach with intrathecal dexamethasone and methotrexate . Springer Semin Immunopathol 1994; 16: 313–321 .

30.

Dong Y , Zhang X , Tang F , Tian X , Zhao Y , Zhang F . Intrathecal injection with methotrexate plus dexamethasone in the treatment of central nervous system involvement in systemic lupus erythematosus . Clin Med J (Engl) 2001; 114: 764–766 .